Can a One-Time gene fix cure wilson disease?

NCT ID NCT06663878

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests an experimental gene therapy called MWAV201 in adults with Wilson disease, a genetic condition that causes copper to build up in the body. The treatment uses a harmless virus to deliver a corrected gene, potentially restoring the body's ability to remove copper. The study focuses on safety and tolerability, while also measuring copper levels in the blood and urine to see if the therapy is working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MWAV201, a nonreplicating recombinant gene transfer vector
What this could lead to
If successful, this gene therapy could provide a one-time treatment that corrects the underlying genetic defect in Wilson disease, potentially reducing or eliminating the need for lifelong medication.
What could go wrong
This is an early-stage, dose-escalation study with only 9 participants, so safety and efficacy are not yet established. Gene therapy carries risks such as immune reactions or unintended effects, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WILSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200092, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.